TomoTherapy (NASD: TTPY) provides a revolutionary, cost-effective radiation treatment system that delivers conformal radiation therapy to cancer patients while limiting damage to surrounding healthy tissues.
Missing: TomoTherapy's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: TomoTherapy's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
TomoTherapy has filed 1 patent.
Radiation therapy, Medical physics, Radiobiology, Radiology, Radioactivity
Radiation therapy, Medical physics, Radiobiology, Radiology, Radioactivity
Latest TomoTherapy News
Feb 10, 2022
- Phase III, randomized controlled trial results highlight patient reported outcomes at 10 years'follow-up - TomoTherapy delivered hypofractionated radiotherapy was superior to conventional radiotherapy in maintaining patients' heart and lung functioning, enabling them to more easily perform daily and leisure time activities, and/or work News provided by Share this article Share this article SUNNYVALE, Calif., Feb. 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY ) announced today that data from a phase III, randomized controlled trial, TomoBreast, indicate post-surgery hypofractionated radiotherapy delivered with the TomoTherapy® System is superior to conventional radiotherapy in preserving long-term heart and lung functioning in women with early breast cancer. An analysis of patient reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy - a significant improvement above the 66.9% achieved with conventional radiotherapy. The single-center trial results were published online in BMC Cancer . "Our global team is committed to developing radiotherapy solutions that enable care teams to improve their patients' lives. The TomoBreast data show we are on the right path. This analysis of patient-driven, Real-World Evidence (RWE) is important because it suggests that patients treated with the TomoTherapy System are less likely than those receiving conventional radiotherapy to experience the debilitating heart and lung side effects that make breathing difficult and interfere with a person's ability to take part in even the most routine daily activities. Additionally, the overall course of treatment was significantly shorter for TomoTherapy treated patients enabling them to get back to living their lives, faster," said Philippe Degreze, Ph.D., vice president, downstream marketing & communications channels at Accuray. The TomoTherapy platform, including the next-generation Radixact® System , is the first in the world capable of helical radiation delivery. Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivered from multiple 360 degree rotations around the patient, providing greater control of the radiation dose so it conforms precisely to the tumor and helps minimize dose to healthy tissue and sensitive organs. Previous reports of the TomoBreast trial showed treatment with the TomoTherapy System improved the uniformity of the dose delivered to the tumor, decreased the dose to the heart and lung, and reduced heart and lung related side effects, signifying that the system's unique architecture helps improve the accuracy of the treatment. "This most recent TomoBreast trial analysis reinforces the outcomes seen in previous clinical evaluations and demonstrates the potential of the TomoTherapy System to make a meaningful difference in breast cancer patients' daily lives. The improvement in cardiorespiratory-related functioning experienced by patients treated with the system was remarkable considering a high proportion of them received concurrent medication and were current or ex-smokers receiving lymph node irradiation – both of which can increase the potential risk of side effects," said Prof Mark De Ridder, head of the radiotherapy department of UZ Brussel, Vrije Universiteit Brussel, Belgium. About the Phase III Trial TomoBreast is a single center phase III prospective, randomized controlled trial comparing accelerated adjuvant radiotherapy with the TomoTherapy® System (TT), versus conventional post-surgery radiotherapy (CR) for breast cancer designed to test the hypothesis that TT might reduce lung-heart toxicity. Patients receiving radiotherapy delivered with the TT underwent treatment five days per week for three weeks, while those receiving conventional radiotherapy had treatment five days per week for five weeks. Eligible patients were women ≥18 years old with histologically proven stage I or II (early) invasive breast cancer who had surgery (lumpectomy or mastectomy) with clear resection margins. 123 women participated, 64 were randomized to receive CR (control arm), 59 to receive treatment with TT (experimental arm). The trial was conducted from 2007–2011 at the Universitair Ziekenhuis Brussel (UZ Brussel), Belgium. About Accuray Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook , LinkedIn , Twitter , and YouTube . Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations related to the TomoTherapy platform, including related to treatment of breast cancer; clinical applications; clinical results; patient experiences and outcomes, and Accuray Incorporated's leadership position in radiation oncology innovation and technologies. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product offerings and improvements; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products for certain users and such other risks identified under the heading "Risk Factors" in the company's quarterly report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on January 28, 2022, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements. Media Contacts:
TomoTherapy Frequently Asked Questions (FAQ)
When was TomoTherapy founded?
TomoTherapy was founded in 1997.
Where is TomoTherapy's headquarters?
TomoTherapy's headquarters is located at 1240 Deming Way, Madison.
What is TomoTherapy's latest funding round?
TomoTherapy's latest funding round is IPO.
How much did TomoTherapy raise?
TomoTherapy raised a total of $80.4M.
Who are the investors of TomoTherapy?
Investors of TomoTherapy include Venture Investors, Open Prairie Ventures, Endeavor Group, State of Wisconsin Investment Board, Ascension Ventures and 8 more.
Who are TomoTherapy's competitors?
Competitors of TomoTherapy include CyrusOne, CivaTech Oncology, AlterG, Keystone Dental, TNI medical, eNeura Therapeutics, Light Sciences Oncology, Augmenix, Game Ready, Tactile Medical and 16 more.
Compare TomoTherapy to Competitors
Mercator MedSystems has developed a broad-based therapeutic platform that allows clinicians to accurately and efficiently deliver drugs and biologics such as stem cells to tissues deep in the body, treating the root cause of significant medical conditions. The company utilizes its family of Micro-Infusion Catheters for targeted treatments via the vascular system, including peripheral artery disease (PAD) and resistant hypertension (HTN); and via the bronchial tree, including malignant airway obstruction secondary to lung cancer. The company's 510(k)-cleared and CE-Marked Cricket and Bullfrog Micro-Infusion Catheters are vascular-access systems that are able to inject drugs, genes, and cells safely through vessel walls into deep tissues without major surgery.
Kinetic Muscles Inc, KMI, engineers and manufactures products for stroke recovery. Used in physical therapy and occpational therapy clinics, KMI's products for stroke rehabilitation help improve the quality of life of stroke survivors.
Catheter Connections develops vascular access products that can help protect patients from life-threatening infections during infusion therapy. The company's flagship product, DualCap, a sterile, single-use device containing two disinfecting caps - one for the IV catheter needleless luer access valve (also known as the needleless injection site, port or valve) and one for the male luer connector at the end of the IV tubing - is an FDA-cleared device for disinfection and protection of both the IV catheter needleless luer access valve and the male luer connector at the end of the IV tubing. DualCap helps to prevent intraluminal contamination, the most common way IV connectors contribute to infections in long-term catheter use.
eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.
Calypso Medical provides technologies in the radiation oncology market
Radiation Shield Technologies (RST) is the world leader in the research, design and production of personal protection systems for ionizing and nuclear radiation. The company's core technology, DemronTM , is specifically engineered to combine radiation protection with "ease of use" in order to maximize effective radiological defense. RST's primary goal is to ensure that all DemronTM products are of the highest protective quality. This is achieved by working closely with the company's end users, developing new standards of personal radiation protection, and meeting the specific needs of those groups most at risk of exposure. After almost a decade of development, RST is proud to introduce DemronTM to the industries, governments and everyday people who, until now, have had no options for true personal radiation protection.n
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.